Definitive Proxy Filed for Catalyst Pharma's $4.1B Acquisition by Angelini Pharma
Summary
Catalyst Pharmaceuticals filed its definitive proxy statement, setting the stage for a shareholder vote on July 8, 2026, to approve its $4.1 billion cash acquisition by Angelini Pharma at $31.50 per share.
Key Events
-
Shareholder Meeting Scheduled
A special meeting is set for July 8, 2026, for shareholders to vote on the merger. The record date for voting is June 3, 2026.
-
Merger Agreement Details
Angelini Pharma will acquire Catalyst Pharmaceuticals for $31.50 per share in cash, representing a 21% premium to the unaffected closing price on April 22, 2026.
-
Board Unanimously Recommends Merger
Catalyst's Board of Directors unanimously determined the merger is fair and in the best interests of shareholders, recommending a 'FOR' vote on all proposals.
-
Insider Voting Agreements
Directors and executive officers, collectively owning approximately 5.5% of outstanding shares, have entered into voting agreements to support the merger.
Analysis
Catalyst Pharmaceuticals has filed its definitive proxy statement (DEFM14A) for the special shareholder meeting on July 8, 2026, to vote on its acquisition by Angelini Pharma for $31.50 per share in cash. This filing provides shareholders with all necessary information to approve the $4.1 billion transaction, which represents a significant premium to the company's unaffected share price. The board of directors unanimously recommends the merger, and key insiders have committed to vote their shares in favor, indicating strong internal conviction in the deal's value.
At the time of this filing, CPRX was trading at $31.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $19.05 to $32.56. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.